Back

Renal response to a dual vasopressin antagonist in acute heart failure: a post-hoc analysis from the AVANTI trial

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Haemodynamics in acute heart failure Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Lucija Cosic

University Medical Centre Groningen, Groningen (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Utility of NT-proBNP for detecting heart failure and assessing prognosis in elderly myocardial infarction survivors: insights from the OMEMI trial
Professor P. Myhre (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
The effect of Pecavaptan in patients with heart failure with reduced versus preserved ejection fraction - a post hoc analysis of the AVANTI trial
Mr G. Voordes (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Oxygen uptake recovery and impaired cardiac reserve capacity: interaction with tau parameter
Doctor G. Crisci (Hasselt, BE)
Abstract Slides

Access the full session

Session thumbnail
Haemodynamics in acute heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
The effect of Pecavaptan in patients with heart failure with reduced versus preserved ejection fraction - a post hoc analysis of the AVANTI trial
thumbnail
Congress Presentation
Thiazides attenuate the diuretic response to pecavaptan, a dual vasopressin receptor antagonist, in hospitalized heart failure patients
thumbnail
Congress Presentation
Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources